S&P 500 7,323.63 −0.23%
Nasdaq 24,429.89 +0.42%
S&P/TSX 34,578.05 −2.09%
Apple 352.45 +0.15%
Nvidia 150.96 −2.89%
Microsoft 508.29 +0.40%
Shopify 199.78 −1.50%
Royal Bank 272.26 −3.11%
CAD/USD 0.6993 −0.01%
PRE-MKT · 05:50 ET
Market ClerkRecap
Thu Nov 19 · pre-market7 signals on Nov 18520 insider buys this week · $248.1MCIRO short report next: Nov 30The week ahead

XFOR

X4 Pharmaceuticals, Inc
NASDAQ · HEALTH CARE · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
2.98
−0.11 −3.56%
USD · close Nov 18

A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up

Financials

SEC XBRL · 49 PERIODS · WHOLE USD

By quarter

PeriodRevenueYoYGross marginOperating incomeNet incomeYoYEPSOp. cash flowCapexFree cash flowFiled
Q3 2026 · Sep 30$2.8M+75.0%81.7%−$20M−$20.2M—-0.16−$20.2M——Nov 4
Q2 2026 · Jun 30$2.4M+41.2%32.6%−$16.4M−$16.2M—-0.13−$20.8M——Nov 4
Q1 2026 · Mar 31$2.5M+177.8%76.1%−$20.3M−$20.2M−7277.7%-0.16−$19.6M——Nov 4
Q4 2025 · Dec 31derived$2.2M+46.7%83.5%−$23.7M−$23.9M—1.00−$15.5M$0−$15.5MMar 17
Q3 2025 · Sep 30$1.6M+185.7%78.1%−$27.5M−$29.8M—-0.69−$27.8M$0−$27.8MNov 4
Q2 2025 · Jun 30$1.7M+202.0%80.8%−$26.2M−$25.7M−128.3%-3.47−$29.9M$0−$29.9MNov 4
Q1 2025 · Mar 31$900K—-424.0%−$9.4M$282K—0.04−$12.4M$0−$12.4MNov 4
Q4 2024 · Dec 31derived$1.5M—79.9%−$35.7M−$39.8M—-5.94−$33M$41K−$33MMar 17
Q3 2024 · Sep 30$560K—59.5%−$34.5M−$36.7M—-5.48−$34M$92K−$34.1MNov 5
Q2 2024 · Jun 30$563K—52.4%$71.1M$90.8M—13.57−$63.9M$134K−$64MNov 5
Q1 2024 · Mar 31$0——−$37.3M−$51.8M—-7.77−$33.6M$59K−$33.7MNov 5
Q4 2023 · Dec 31derived$0——−$25.2M−$19.1M—-16.59−$27.7M$35K−$27.8MMar 17

By fiscal year

YearRevenueGross marginOperating incomeNet incomeNet marginEPSOp. cash flowCapexFree cash flowBuybacksDividends paid
FY2025 · to Dec 31$6.5M11.4%−$86.9M−$79.2M-1218.4%-1.87−$85.6M$0−$85.6M——
FY2024 · to Dec 31$2.6M69.3%−$36.4M−$37.5M-1440.4%-5.59−$130.9M$326K−$131.2M——
FY2023 · to Dec 31$0—−$107.5M−$101.2M—-17.07−$96.5M$60K−$96.6M$0—
FY2022 · to Dec 31$0—−$87.6M−$93.9M—-1.52−$77.1M$103K−$77.2M$0—
FY2021 · to Dec 31$0—−$85.1M−$88.7M—-3.99−$70.9M$615K−$71.5M$2M—
FY2020 · to Dec 31$3M—−$59.9M−$62.1M-2071.0%-3.09−$58.8M$1.4M−$60.2M$0—

Every number comes from X4 Pharmaceuticals, Inc's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.

Watch XFOR. Know when insiders buy.
One email the day a filing lands. Free.